 <h1>Ultomiris Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>ravulizumab</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about ravulizumab. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Ultomiris.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ravulizumab: intravenous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Injectable)</p><p>Warning: Serious Meningococcal InfectionsLife-threatening meningococcal infections/sepsis have occurred in patients treated with ravulizumab-cwvz. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies. Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of ravulizumab-cwvz, unless the risks of delaying ravulizumab-cwvz therapy outweigh the risk of developing a meningococcal infection. Vaccination reduces, but does not eliminate, the risk of meningococcal infections Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected. Ravulizumab-cwvz is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the ravulizumab-cwvz REMS, prescribers must enroll in the program.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ravulizumab (the active ingredient contained in Ultomiris) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking ravulizumab:</p><p>
<i>More common</i>
</p><ul>
<li>Bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>blurred vision</li>
<li>body aches or pain</li>
<li>chills</li>
<li>cough</li>
<li>difficulty with breathing</li>
<li>dizziness</li>
<li>ear congestion</li>
<li>extremely high fever or body temperature</li>
<li>fast, shallow breathing</li>
<li>fast, weak heartbeat</li>
<li>fever</li>
<li>headache</li>
<li>loss of voice</li>
<li>muscle cramps</li>
<li>nervousness</li>
<li>pale, clammy skin</li>
<li>pounding in the ears</li>
<li>rapid weight gain</li>
<li>runny or stuffy nose</li>
<li>sneezing</li>
<li>slow or fast heartbeat</li>
<li>sore throat</li>
<li>thirst</li>
<li>tingling of the hands or feet</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ravulizumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>difficulty having a bowel movement (stool)</li>
<li>fear</li>
<li>hair loss or thinning of the hair</li>
<li>muscle spasms</li>
<li>nausea or vomiting</li>
<li>pain in the arms or legs</li>
<li>stomach pain</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Difficulty with moving</li>
<li>joint pain</li>
<li>muscle pain or stiffness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ravulizumab: intravenous solution</i></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immunogenicity, increased susceptibility to encapsulated bacterial infections (especially infections caused by Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae), life-threatening meningococcal infections (e.g., septicemia and/or meningitis)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Rare</b> (0.01% to 0.1%): Infusion reactions (e.g., lower back pain, drop in blood pressure, infusion-related pain)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Pain in extremity, arthralgia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (e.g., nasopharyngitis, upper respiratory tract infection, oropharyngeal pain, viral</p>
<p>upper respiratory tract infection, rhinitis, respiratory tract infection, rhinorrhea, pharyngitis, upper respiratory tract inflammation) (39%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Hyperthermia, pyrexia<sup>[Ref]</sup></p><h3>General</h3><p>The most frequent adverse drug reactions (greater than 10%) with are upper respiratory tract infection and headache.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (32%)</p>
<p><b>Common</b> (1% to 10%): Dizziness<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, nausea, abdominal pain<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Ultomiris (ravulizumab)." Alexion Pharmaceuticals Inc, Cheshire, CT. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Ultomiris (ravulizumab)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: selective immunosuppressants</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ultomiris &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hemolytic Uremic Syndrome</li>
<li>Paroxysmal Nocturnal Hemoglobinuria</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ravulizumab: intravenous solution</i></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immunogenicity, increased susceptibility to encapsulated bacterial infections (especially infections caused by Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae), life-threatening meningococcal infections (e.g., septicemia and/or meningitis)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Rare</b> (0.01% to 0.1%): Infusion reactions (e.g., lower back pain, drop in blood pressure, infusion-related pain)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Pain in extremity, arthralgia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (e.g., nasopharyngitis, upper respiratory tract infection, oropharyngeal pain, viral</p><p>upper respiratory tract infection, rhinitis, respiratory tract infection, rhinorrhea, pharyngitis, upper respiratory tract inflammation) (39%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Hyperthermia, pyrexia<sup>[Ref]</sup></p><h3>General</h3><p>The most frequent adverse drug reactions (greater than 10%) with are upper respiratory tract infection and headache.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (32%)</p><p><b>Common</b> (1% to 10%): Dizziness<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, nausea, abdominal pain<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Ultomiris (ravulizumab)." Alexion Pharmaceuticals Inc, Cheshire, CT. </p><h2>More about Ultomiris (ravulizumab)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: selective immunosuppressants</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ultomiris &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hemolytic Uremic Syndrome</li>
<li>Paroxysmal Nocturnal Hemoglobinuria</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>